Anhedonia – the reduced ability to experience or respond to pleasure – is an important symptom domain for many psychiatric disorders. It is particularly relevant to depression and other mood disorders and it is a diagnostic criterion of a major depressive episode. Developing safe and effective pharmacological interventions for anhedonia is a critical public health need. The current chapter will review the state of the field with respect to both the efficacy of currently available pharma-cotherapies for anhedonia and the recent clinical research focusing on new brain targets, including the kappa-opioid receptor and the KCNQ2/3 receptors. The evidence for anti-anhedonic effects of ketamine and psychedelic agents will be reviewed, as well.

Original languageEnglish
Title of host publicationCurrent Topics in Behavioral Neurosciences
PublisherSpringer Science and Business Media Deutschland GmbH
Number of pages24
StatePublished - 2022

Publication series

NameCurrent Topics in Behavioral Neurosciences
ISSN (Print)1866-3370
ISSN (Electronic)1866-3389


  • Anhedonia
  • Antidepressant
  • Depression
  • KCNQ
  • Ketamine
  • Opioid
  • Psychedelic
  • Reward


Dive into the research topics of 'Pharmacological Treatments for Anhedonia'. Together they form a unique fingerprint.

Cite this